Adagene (FRA:978) EV-to-FCF: (As of Jul. 03, 2026)


FRA:978 Adagene Inc FRA:978
42 GF Score
Price €4.02
GF Value €12.68
! 5 Warning Signs
View Full Analysis

What is Adagene EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Adagene's Enterprise Value is €205.94 Mil. Adagene's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil. Therefore, Adagene's EV-to-FCF for today is .

The historical rank and industry rank for Adagene's EV-to-FCF or its related term are showing as below:

FRA:978' s EV-to-FCF Range Over the Past 10 Years
Min: -37.32   Med: -0.64   Max: 2.8
Current: -14.49

During the past 8 years, the highest EV-to-FCF of Adagene was 2.80. The lowest was -37.32. And the median was -0.64.

FRA:978's EV-to-FCF is ranked worse than
100% of 332 companies
in the Biotechnology industry
Industry Median: 16.26 vs FRA:978: -14.49

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-07-03), Adagene's stock price is €4.02. Adagene's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.324. Therefore, Adagene's PE Ratio (TTM) for today is At Loss.


Adagene  (FRA:978) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Adagene's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=4.02/-0.324
=At Loss

Adagene's share price for today is €4.02.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Adagene's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.324.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Adagene EV-to-FCF Related Terms


Adagene EV-to-FCF Historical Data

* Premium members only.

The historical data trend for Adagene's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adagene EV-to-FCF Chart

Adagene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EV-to-FCF
Get a 7-Day Free Trial -4.04 1.19 0.08 -0.91 -1.36

Adagene Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.00 -0.91 0.00 -1.36

FRA:978 vs RNAC, LYEL, ALXO: EV-to-FCF Comparison

For the Biotechnology subindustry, Adagene's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adagene EV-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adagene's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Adagene's EV-to-FCF falls into.


FRA:978
42GF Score
Adagene Inc FRA:978
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adagene EV-to-FCF Calculation

Adagene's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=205.941/0
=

Adagene's current Enterprise Value is €205.94 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Adagene's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Adagene (FRA:978) Overvalued in 2026?

Based on GuruFocus' analysis, Adagene stock appears to be undervalued. The current stock price of €4.02 is trading 68.3% below its estimated GF Value™ of €12.68.

Key valuation signals for FRA:978:

  • EV-to-FCF:
  • GF Value™: €12.68 vs. price of €4.02 (68.3% below fair value)
  • GF Score™: 42/100 with 5 warning signs

No single metric tells the full story. See the FRA:978 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Adagene Business Description

Other Exchanges ADAG:USA
Address Xinghu Street, Suzhou Industrial Park, 4th Floor, Building C14, No. 218, Jiangsu Province, Suzhou, CHN, 215123
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
42GF Score

Get the complete analysis for FRA:978

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.02
Price
€12.68
GF Value